rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A large number of studies in the past decade have tried to dissect the relevance and the function of the V600E mutation in controlling oncogenesis and progression of thyroid cancer.
|
24828987 |
2015 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation is an early event in thyroid carcinogenesis, and is associated with distinctive morphology and aggressive features even in papillary thyroid microcarcinomas.
|
22918165 |
2013 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
|
15782118 |
2005 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conclusions.-The T1799A BRAF mutation does not appear to play a role in the tumorigenesis of CMVPTC.
|
19415957 |
2009 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
|
18032947 |
2007 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further analyses suggested a complex mechanism driven by mutation BRAF (V600E) on melanoma tumorigenesis that disturbs specific cancer-related genes, pathways, and methylation modifications.
|
25890285 |
2015 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis.
|
22586120 |
2012 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings.
|
24717435 |
2014 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we report that Mps1/AKT and B-Raf(WT)/ERK signaling form an auto-regulatory negative feedback loop in melanoma cells; notably, oncogenic B-Raf(V600E) abrogates the negative feedback loop, contributing the aberrant Mps1 functions and tumorigenesis.
|
23726842 |
2013 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we studied the expression and function of the exportin cellular apoptosis susceptibility (CAS) in thyroid carcinogenesis and its link to the BRAF(V600E) mutation.
|
26892809 |
2016 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast to other Braf-induced mouse models of tumorigenesis (i.e., melanomas and lung), in which knock-in of Braf(V600E) induces mostly benign lesions, Braf-expressing thyrocytes become transformed and progress to invasive carcinomas with a very short latency, a process that is dampened by treatment with an allosteric MEK inhibitor.
|
21220306 |
2011 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In particular, evidence for oncogene-induced melanocyte senescence as natural means to prevent tumorigenesis has been obtained in nevi with mutated B-Raf(V600E).
|
18806824 |
2008 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutation in the B RAF at V600E has been well implicated in the carcinogenesis that makes it as an attractive therapeutictarget.
|
28472910 |
2017 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings provide a molecular linkage between the LKB1-AMPK and the RAF-MEK-ERK pathways and suggest that suppression of LKB1 function by B-RAF V600E plays an important role in B-RAF V600E-driven tumorigenesis.
|
19187764 |
2009 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, an alternative pathway of tumorigenesis has been identified in the colorectum associated with serrated precursor lesions, variable levels of microsatellite instability (MSI-V), and driven in part by activating mutations in the BRAF proto-oncogene (V599E).
|
15765445 |
2005 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specific mutations of RAF kinases, such as the prevalent BRAF(V600E) mutation in melanoma, or defects in upstream signaling or feedback loops cause decoupled kinase activities which lead to tumorigenesis.
|
28466200 |
2019 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specifically, both the initial and recurrent tumors of the patient showed the same BRAF V600E mutation, which refutes previous suggestions that BRAF mutations may be limited to intracranial PXAs and also shows that BRAF mutations may occur earlier in PXA tumorigenesis.
|
27956254 |
2017 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Targeted reduction of mutant (V599E)B-Raf expression (activity) in melanoma cells before tumor formation inhibited tumorigenesis by reducing the growth potential of melanoma cells.
|
15781657 |
2005 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The B-Raf(V600E) mutant, found in 65% of human melanomas, drives constitutive activation of the extracellular signal-regulated kinase (ERK) pathway and is implicated in tumorigenesis.
|
18071315 |
2008 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The coexistence of LCH and ECD in the same biopsy and the BRAF (V600E) mutation status in both histologic types support the recent re-classification of the histiocytic disorder into LCH, ECD, and "mixed histiocytosis", which reflects tumorigenesis for all three from a common progenitor cell.
|
26466952 |
2016 |
rs113488022
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The data suggest that coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence.
|
26028035 |
2016 |